Development Status: The technology is currently in the pre-clinical stage of development.

Inventors: Suresh K. Arya (NCI).

Publication: SK Arya *et al.* Human immunodeficiency virus type 2 lentivirus vectors for gene transfer: expression and potential for helper virus-free packaging. Hum Gene Ther. 1998 Jun 10;9(9):1371–1380.

Patent Status: U.S. Patent No. 6,790,657 issued 14 Sep 2004, entitled ''Lentivirus Vector System'' (HHS Reference No. E–231–1998/0-US–03); U.S. Patent Application No. 10/731,988 filed 09 Dec 2003, now allowed, entitled ''Lentivirus Vector System'' (HHS Reference No. E–231–1998/0-US–04).

Licensing Status: Available for exclusive or non-exclusive licensing.

Licensing Contact: David Lambertson, Ph.D.; 301/435–4632; *lambertsond@od.nih.gov*.

Methods and Compositions of Chemokine-Tumor Antigen Fusion Proteins as Cancer Vaccines

Description of Technology: Tumor cells are known to express tumor specific antigens on the cell surface. These antigens are believed to be poorly immunogenic, largely because they represent gene products of oncogenes or other cellular genes which are normally present in the host. As a result, poor immunogenicity of relevant cancer antigens has proven to be a major obstacle to successful immunotherapy with tumor vaccines. Thus, there is a need for a more potent vaccine to elicit an immune response effective in the treatment or prevention of cancer.

The current invention embodies a fusion protein comprising of a chemokine and tumor antigen. The inventors reported in several peer-reviewed manuscripts that these fusion proteins represent potential vaccines for use against cancer. More specifically, the inventors have developed a vaccine construct that expresses fusion protein comprising human monocyte chemotactic protein-3 fused with tumor antigens, such as lymphoma-derived Id or breast cancer Muc-1. Administration of the fusion protein, or a nucleic acid encoding the fusion protein, elicits a specific immune response directed against the tumor antigen or protein, thereby inhibiting the growth of cells expressing this antigen or protein.

Applications and Modality: Potential immunotherapy for cancer.

Market: 600,000 deaths from cancer related diseases estimated in 2006.

Development Status: This technology is currently in the pre-clinical stage of development.

Inventors: Larry Kwak (NCI) and Arya Biragyn (NIA).

Patent Status: U.S. Patent No. 6,562,347 issued 13 May 2003 (HHS Reference No. E–107–1998–0-US–03).

Licensing Status: Available for exclusive and non-exclusive licensing.

Licensing Contact: Jennifer Wong; 301/435–4633; *wongje@mail.nih.gov.*

Dated: January 31, 2007.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. E7–1931 Filed 2–6–07; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Cancer Institute Board of Scientific Advisors.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: National Cancer Institute Board of Scientific Advisors.

Date: March 5–6, 2007.

Time: March 5, 2007, 8 a.m. to 6 p.m.

Agenda: Director's Report: Ongoing and New Business; Reports of Program Review Group(s); and Budget Presentation; Reports of Special Initiatives; RFA and RFP Concept Reviews; and Scientific Presentations.

Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892.

Time: March 6, 2007, 8 a.m. to 1 p.m.

Agenda: Reports of Special Initiatives; RFA and RFP Concept Reviews; and Scientific Presentations.

Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892.

Contact Person: Paulette S. Gray, PhD, Executive Secretary, Director, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, 8th Floor, Rm. 8001, Bethesda, MD 20892, 301–496–5147, *grayp@mail.nih.gov.*

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH as instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: *deainfo.nci.nih.gov/advisory/bsa.htm,* where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: January 31, 2007.

Anna Snouffer,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 07–519 Filed 2–6–07; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel, Research Project in Cardiothoracic Surgery.

Date: March 7–8, 2007.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn Georgetown, 2101 Wisconsin Avenue, NW., Washington, DC 20007.

Contact Person: Shelly S. Sehnert, PhD., Scientific Review Administrator, Review